

# 고혈압 치료에 있어서 ACE 저해제와 Losartan

유 언 호

## ACE Inhibitors and Losartan in the Management of Hypertension

Un Ho Ryoo, M.D.

Division of Cardiology, Department of Internal Medicine, Chung-Ang University Hospital,  
Seoul, Korea

Angiotensin (ACE inhibitor) .<sup>8)</sup>  
 . ACE Losartan potassium  
 , placebo losartan po-  
 , tassium  
 . (first-dose hypotension)  
 . , ACE inhibitor  
 placebo  
 p15 참조  
 . angioedema, (renal  
 dysfunction), (cough)  
 3-7) . 가  
 1-7)  
 Losartan potassium  
 nonpeptide angiotensin II . Losartan potassium hydrochlo-  
 (AII) receptor antagonist . AII sub- rothizide losartan potassium  
 type 1(AT<sub>1</sub>) receptor placebo . Angiotensin  
 AII . II(AII) subtype 1 receptor(AT<sub>1</sub>) AII  
 E3174  
 1 1 , , Na/ ,  
 24 .  
 , losartan potassium 50 100mg 1 1 . Losartan potassium  
 enalapril, atenolol felodipine ex- AT<sub>1</sub> receptor  
 tended release(ER) 가 AII . E3174  
 . Losartan potassium hydrochlorothiazide 10  
 AT<sub>1</sub> receptor . AII  
 1/3 15 20

<sup>8)</sup>.  
 losartan potassium  
 renin All  
 aldosterone , bradykinin  
 LVH  
 , stroke  
 가 model  
 fibrinoid necrosis <sup>8)</sup>.  
 losartan potassium  
 uricosuric effect  
 losartan potassium NIDDM  
 proteinuria . lipids/lipo -  
 proteins <sup>1,8)</sup>.  
 Losartan potassium E3174  
 가 , <sup>8)</sup>.  
 2800 double - blind  
 trials losartan potassium  
 (14.1%), (6.5%), (4.1%),  
 / (3.8%), (3.1%)  
 , placebo losartan potassium  
 ( 50mg  
 0.5%) <sup>8)</sup>.  
 ACE 가  
 , losartan potassium(3.1%)  
 placebo(2.6%)  
 . ACE losartan  
 potassium(17 29%), placebo(35%) hy -  
 drochlorothiazide(25 34%)  
 lisinopril(62 72%)  
<sup>1,3-7)</sup>.

kininogen - kinin(bradykinin) system  
 가 , ACE(kininase)  
 bradykinin 가  
 . Bradykinin pro - inflammatory  
 peptides( substance P, neuropeptide Y)  
 histamine  
 cough reflex hypersensitivity  
 Angioneurotic edema <sup>9)</sup>.  
 . Ca  
 steroid (indomethacin sulindac)  
 . histamine  
 가  
<sup>9)</sup>.  
 (placebo control ) (14%)  
 felodipine ER , (7.4%) (4.4%)  
 atenolol losartan potassium  
 . Liver enzyme <sup>8)</sup>.  
 Dose - finding studies losartan 1 1  
 50mg 100mg  
 ,  
 8 12  
 8 13mmHg , trough  
 percentage responders 가  
 losartan potassium enalapril,  
 atenolol, felodipine ER 가 . Lo-  
 sartan potassium 1  
 6 <sup>8)</sup>.  
 12 (noncomparative studies)  
 30% losartan potassium  
 hydrochlorothiazide(12.5mg 25mg)  
 , 22% losartan potassium  
 , atenolol / calcium channel  
 blocker . Losartan potassium  
 18mmHg  
 . Losartan potassium hydrochlorothiazide  
 4 6mmHg  
 felodipine ER 가 <sup>8)</sup>.  
 losartan potassium

1 100mg .

1 1 50mg .

25mg .

1 25mg 8) .

creatinine 2mg/dl

ACE

fosinopril , creatinine

10) .

ACE 가

11) . AII 가

prejunctional neuronal AII type 1 receptors , ACE

ACE

renin - angiotensin

( angioedema ) AII

. ACE renin - angiotensin

AI AII .

renin - angiotensin meta-

bolic pathway AII 가

ACE

AII가

AII 가 ACE

12) .

AT<sub>1</sub> receptor antagonist

가 ,

가 . Losartan

## References

- 1) 박대균 · 이명목 · 채인호 · 이무용 · 김효수 · 손대원 · 오병희 · 박영배 · 최윤식 : 로자탄 대 포시노프릴의 고혈압환자에서 항고혈압 효과, 안정성 및 내약성의 비교. 순환기 28 (1), 1998
- 2) Pitt B : Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and Congestive heart failure : Implications for clinical practice. Cardiology 86 Suppl 1 : 41-45, 1995
- 3) Lacourciere Y, Lefebvre J : Modulation of renin-angiotensin-aldosterone system and cough. Can J Cardiol 11 suppl F : 33F-39F, 1995
- 4) Chan P, Tomlinson B, Huang TY, Ko JT, Lin TS, Lee YS : Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 37 (3) : 253-257, 1997
- 5) Ramsay LE, Yeo WW : ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. J Hum Hypertens suppl 5 : S51-S54, 1995
- 6) Lacourciere Y, Lefebvre J, Nakhle G, Faison EP, Snaveley DB, Nelson EB : Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists : The design of a prospective, controlled study. J Hypertens suppl 12 (2) : S49-S53, 1994
- 7) Markham A, Goa KL : Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54 (2) : 299-311, 1997
- 8) Goa KL, Wagstaff AJ : Losartan potassium ; A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51 (5) : 820-845, 1996
- 9) Karlberg BE : Cough and inhibition of renin-angiotensin system. J Hypertens suppl 11 : (3) : S49-S52, 1993
- 10) Pitt B : ACE inhibitors in heart failure : Prospects and limitation. Cardiovasc Drugs Ther 11 suppl 1 : 285-290, 1997
- 11) Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedovania PC, Ney DE, Snaveley DB, Chang PI : Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet 15 : 349 (9054) : 747-752, 1997
- 12) Rush JE, Rajfer SI : Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure. J Hypertens suppl 11 (3) : S69-S71, 1993